Rebif 12 M IU (44 mcg/0.5mL) Solution For Injection (SC) Filipina - Inggris - FDA (Food And Drug Administration)

rebif 12 m iu (44 mcg/0.5ml) solution for injection (sc)

merck, inc.; distributor: zuellig pharma corp - interferon beta-1a - solution for injection (sc) - 12 m iu (44 mcg/0.5ml)

Primaxin Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

primaxin

merck sharp & dohme (new zealand) limited - cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage).; imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).;   - powder for infusion - 500mg/500mg - active: cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage). imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).   excipient: sodium bicarbonate

Varivax Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

varivax

merck sharp & dohme (new zealand) limited - varicella vaccine 1350 pfu (oka/merck);   - injection with diluent - 1350 pfu - active: varicella vaccine 1350 pfu (oka/merck)   excipient: dibasic sodium phosphate dodecahydrate gelatin monobasic potassium phosphate monosodium glutamate potassium chloride sodium chloride sucrose urea water for injection - varivax is indicated for vaccination against varicella in individuals 12 months of age and older.

ZOSTAVAX  (ZOSTER VACCINE LIVE) Israel - Inggris - Ministry of Health

zostavax (zoster vaccine live)

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - powder and solvent for suspension for injection - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

ZOSTAVAX- zoster vaccine live injection, powder, lyophilized, for suspension
STERILE DILUENT- sterile water injection Amerika Serikat - Inggris - NLM (National Library of Medicine)

zostavax- zoster vaccine live injection, powder, lyophilized, for suspension sterile diluent- sterile water injection

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 19400 [pfu] in 0.65 ml - zostavax® is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. limitations of use of zostavax: - zostavax is not indicated for the treatment of zoster or postherpetic neuralgia (phn). - zostavax is not indicated for prevention of primary varicella infection (chickenpox). do not administer zostavax to individuals with a history of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other component of the vaccine. neomycin allergy manifested as contact dermatitis is not a contraindication to receiving this vaccine. {1} do not administer zostavax to individuals who are immunodeficient or immunosuppressed due to disease or therapy, as serious or fatal disseminated vaccine strain varicella-zoster virus disease may occur. causes of immunodeficiency or immunosuppression may include, but are not limited to, primary or acquired immunodeficiency states, aids or other clinical manifestations of infection with human immunodeficiency

ProQuad Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

proquad

merck sharp & dohme (new zealand) limited - measles vaccine 1000 tcid50 (edmonston b strain (3 log per dose)); mumps virus, jeryl-lynn strain 19952 tcid50 (b level (4.3 log per dose)); rubella virus, wistar ra27/3 strain 1000 tcid50 ((3 log per dose) ); varicella vaccine 9772 pfu (oka/merck strain (3.99 log per dose));   - injection with diluent - 0.5 ml - active: measles vaccine 1000 tcid50 (edmonston b strain (3 log per dose)) mumps virus, jeryl-lynn strain 19952 tcid50 (b level (4.3 log per dose)) rubella virus, wistar ra27/3 strain 1000 tcid50 ((3 log per dose) ) varicella vaccine 9772 pfu (oka/merck strain (3.99 log per dose))   excipient: dibasic potassium phosphate dibasic sodium phosphate gelatin minimum essential medium eagle medium 199 monosodium glutamate phenolsulfonphthalein potassium chloride sodium bicarbonate sodium chloride sorbitol sucrose urea water for injection - proquad is indicated for vaccination against measles, mumps, rubella, and varicella in individuals 12 months through 12 years of age.

Zostavax Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

zostavax

merck sharp & dohme (new zealand) limited - varicella-zoster virus, oka/merck strain, live, attenuated 19400 pfu;   - injection with diluent - 19400 pfu - active: varicella-zoster virus, oka/merck strain, live, attenuated 19400 pfu   excipient: dibasic sodium phosphate monohydrate gelatin monobasic potassium phosphate monosodium glutamate potassium chloride sodium chloride sucrose urea water for injection - zostavax is indicated for: · prevention of herpes zoster (shingles)

MERCK SHARP & DOHME STERILE DILUENT for live virus vaccines  injection prefilled syringe Australia - Inggris - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme sterile diluent for live virus vaccines injection prefilled syringe

merck sharp & dohme (australia) pty ltd - water for injections, quantity: 0.75 ml - diluent, not applicable - excipient ingredients: - for use as a diluent for merck, sharp & dohme live virus vaccines.

Merck Cladribine Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

merck cladribine

pharmacy retailing (nz) ltd t/a healthcare logistics - cladribine 10mg;   - tablet - 10 mg - active: cladribine 10mg   excipient: hydroxypropyl-beta-cyclodextrin magnesium stearate sorbitol water for injection - mavenclad is indicated for the treatment of relapsing-remitting multiple sclerosis (rrms) to reduce the frequency of clinical relapses and to delay the progression of physical disability. following completion of the two treatment courses, no further cladribine treatment is required in years three and four. re-initiation of therapy after year four has not been studied.